Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2016

01-07-2016 | Original Article

Predictable factors for lymph node metastasis in early gastric cancer analysis of clinicopathologic factors and biological markers

Authors: Yi-Wei Wang, Mei-Ling Zhu, Rui-Fen Wang, Wen-Ji Xue, Xue-Ru Zhu, Li-Feng Wang, Lei-Zhen Zheng

Published in: Tumor Biology | Issue 7/2016

Login to get access

Abstract

Predicting lymph node metastasis (LNM) accurately is very important to decide treatment strategies preoperatively. The aim of this study was to explore risk factors that predict the presence of LNM in early gastric cancer (EGC). A total of 230 patients with EGC who underwent curative gastrectomy with lymph adenectomy at Xinhua Hospital from January 2006 to July 2014 were retrospectively reviewed. We studied the relationship between clinicopathological factors, biological markers (p53, ki67, nm23, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), E-cadherin (E-cad), beta-catenin (b-catenin), glutathione S-transferase (GST), and topoisomerase II (Topo II)), and LNM of EGC patients by chi-square test and logistic regression analysis. Meta-analyses were further conducted to review the effects of the proteins (P53, ki67, E-cad, and b-catenin) on LNM in ECG patients. LNM was detected in 42 (18.3 %) of 230 patients. Incidences of LNM was distinct in different tumor size (p = 0.044), depth of submucosal invasion (p < 0.0001), and P53 overexpression (p = 0.004). Multivariate analysis further indentified that large tumor size (≥20 mm, odds ratio (OR) = 2.168, p = 0.041), submucosa (OR = 4.000, p = 0.0005), and P53 overexpression (OR = 3.010, p = 0.022) were independent risk factors of LNM in EGC patients. The meta-analysis revealed a significantly statistical association of P53, ki67, and b-catenin with an increased risk of LNM in EGC patients (P53, OR = 1.81, p = 0.017; ki67, OR = 2.53, p = 0.0003; b-catenin, OR = 0.53, p = 0.01). Tumor size (≥20 mm), the depth of invasion (submucosa), and P53 overexpression may be helpful predictors of LNM in EGC patients. Furthermore, the results of meta-analysis revealed that P53, ki67 overexpression, and abnormal expression of b-catenin may be associated with LNM in EGC. The results need further validation in single large studies.
Literature
1.
Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg. 1981;11:127–39.CrossRefPubMed
2.
Wu CY, Chen JT, Chen GH, Yeh HZ. Lymph node metastasis in early gastric cancer: a clinicopathological analysis. Hepatogastroenterology. 2002;49:1465–8.PubMed
3.
Mouri R, Yoshida S, Tanaka S, Oka S, Yoshihara M, Chayama K. Usefulness of endoscopic ultrasonography in determining the depth of invasion and indication for endoscopic treatment of early gastric cancer. J Clin Gastroenterol. 2009;43:318–22.CrossRefPubMed
4.
Boku T, Nakane Y, Okusa T, Hirozane N, Imabayashi N, Hioki K, et al. Strategy for lymphadenectomy of gastric cancer. Surgery. 1989;105:585–92.PubMed
5.
Popiela T, Kulig J, Kolodziejczyk P, Sierzega M. Long-term results of surgery for early gastric cancer. Br J Surg. 2002;89:1035–42.CrossRefPubMed
6.
Seto Y, Shimoyama S, Kitayama J, Mafune K, Kaminishi M, Aikou T, et al. Lymph node metastasis and preoperative diagnosis of depth of invasion in early gastric cancer. Gastric Cancer. 2001;4:34–8.CrossRefPubMed
7.
Ren G, Cai R, Zhang WJ, Ou JM, Jin YN, Li WH. Prediction of risk factors for lymph node metastasis in early gastric cancer. World J Gastroenterol. 2013;19:3096–107.CrossRefPubMedPubMedCentral
8.
Noh SH, Hyung WJ, Cheong JH. Minimally invasive treatment for gastric cancer: approaches and selection process. J Surg Oncol. 2005;90:188–94.CrossRefPubMed
9.
10.
Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001;48:225–9.CrossRefPubMedPubMedCentral
11.
Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol. 2006;41:929–42.CrossRefPubMed
12.
Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat. 2003;21:258–70.CrossRefPubMed
13.
Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, et al. Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology-Basel. 1999;57:131–7.CrossRef
14.
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–5.PubMed
15.
Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010;17:R245–62.CrossRefPubMed
16.
Backer JM, Mendola CE, Kovesdi I, Fairhurst JL, O’Hara B, Eddy RJ, et al. Chromosomal localization and nucleoside diphosphate kinase activity of human metastasis-suppressor genes NM23-1 and NM23-2. Oncogene. 1993;8:497–502.PubMed
17.
Radovic S, Doric M, Hukic A, Babic M, Kuskunovic S, Spahovic N. Immunohistochemical expression and significance of NM23 suppressor protein in primary gastric adenocarcinoma. Bosn J Basic Med Sci. 2013;13:72–7.PubMedPubMedCentral
18.
Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988;80:200–4.CrossRefPubMed
19.
Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15:69–79.CrossRefPubMed
20.
Jin EH, Lee DH, Jung SA, Shim KN, Seo JY, Kim N, et al. Clinicopathologic factors and molecular markers related to lymph node metastasis in early gastric cancer. World J Gastroenterol. 2015;21:571–7.CrossRefPubMedPubMedCentral
21.
Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J. 1989;8:1711–7.PubMedPubMedCentral
22.
Ozawa M, Ringwald M, Kemler R. Uvomorulin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule. Proc Natl Acad Sci U S A. 1990;87:4246–50.CrossRefPubMedPubMedCentral
23.
Ozawa M, Kemler R. Molecular organization of the uvomorulin-catenin complex. J Cell Biol. 1992;116:989–96.CrossRefPubMed
24.
Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991;113:173–85.CrossRefPubMed
25.
Vleminckx K, Vakaet LJ, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66:107–19.CrossRefPubMed
26.
Geng M, Wang L, Chen X, Cao R, Li P. The association between chemosensitivity and Pgp. GST-pi and Topo II expression in gastric cancer. Diagn Pathol. 2013;8:198.CrossRefPubMedPubMedCentral
27.
Japanese GCA. Japanese classification of gastric carcinoma - 2nd English edition -. Gastric Cancer. 1998;1:10–24.CrossRef
28.
Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.
29.
Hu B, El HN, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251–61.PubMedPubMedCentral
30.
Tanaka M, Kitajima Y, Edakuni G, Sato S, Miyazaki K. Abnormal expression of E-cadherin and beta-catenin may be a molecular marker of submucosal invasion and lymph node metastasis in early gastric cancer. Br J Surg. 2002;89:236–44.PubMed
31.
Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H, et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer. 2015;18:227–38.CrossRefPubMed
32.
33.
MANTEL N, HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
34.
35.
Maehara Y, Orita H, Okuyama T, Moriguchi S, Tsujitani S, Korenaga D, et al. Predictors of lymph node metastasis in early gastric cancer. Br J Surg. 1992;79:245–7.CrossRefPubMed
36.
37.
Tong JH, Sun Z, Wang ZN, Zhao YH, Huang BJ, Li K, et al. Early gastric cancer with signet-ring cell histologic type: risk factors of lymph node metastasis and indications of endoscopic surgery. Surgery. 2011;149:356–63.CrossRefPubMed
38.
Lim MS, Lee HW, Im H, Kim BS, Lee MY, Jeon JY, et al. Predictable factors for lymph node metastasis in early gastric cancer-analysis of single institutional experience. J Gastrointest Surg. 2011;15:1783–8.CrossRefPubMed
39.
Guadagni S, Reed PI, Johnston BJ, De Bernardinis G, Catarci M, Valenti M, et al. Early gastric cancer: follow-up after gastrectomy in 159 patients. Br J Surg. 1993;80:325–8.CrossRefPubMed
40.
Adachi Y, Yasuda K, Inomata M, Shiraishi N, Kitano S, Sugimachi K. Clinicopathologic study of early-stage mucinous gastric carcinoma. Cancer. 2001;91:698–703.CrossRefPubMed
41.
Ohashi S, Okamura S, Urano F, Maeda M. Clinicopathological variables associated with lymph node metastasis in submucosal invasive gastric cancer. Gastric Cancer. 2007;10:241–50.CrossRefPubMed
42.
Kwee RM, Kwee TC. Predicting lymph node status in early gastric cancer. Gastric Cancer. 2008;11:134–48.CrossRefPubMed
43.
44.
Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol. 1995;13:1009–22.CrossRefPubMed
45.
Zheng Y, Wang L, Zhang JP, Yang JY, Zhao ZM, Zhang XY. Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma. World J Gastroenterol. 2010;16:339–44.CrossRefPubMedPubMedCentral
46.
Sasaki O, Kido K, Nagahama S. DNA ploidy, Ki-67 and p53 as indicators of lymph node metastasis in early gastric carcinoma. Anal Quant Cytol Histol. 1999;21:85–8.PubMed
47.
Kanai T, Konno H, Maruyama K, Baba M, Tanaka T, Maruo Y, et al. P53 overexpression and proliferative activity do not correlate with lymph node metastasis in early gastric cancer. Eur Surg Res. 1997;29:35–41.CrossRefPubMed
48.
Jiaqing L, Hokita S, Xiangming C, Natsugoe S, Tanabe G, Baba M, et al. Role of cyclin E and p53 expression in progression of early gastric cancer. Gastric Cancer. 1998;1:160–5.CrossRefPubMed
49.
Goncalves AR, Carneiro AJ, Martins I, de Faria PA, Ferreira MA, de Mello EL, et al. Prognostic significance of p53 protein expression in early gastric cancer. Pathol Oncol Res. 2011;17:349–55.CrossRefPubMed
50.
Goishi H, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, et al. Predictive value of Cathepsin D and Ki-67 expression at the deepest penetration site for lymph node metastases in gastric cancer. Oncol Rep. 2000;7:713–8.PubMed
51.
Cai J, Ikeguchi M, Tsujitani S, Maeta M, Liu J, Kaibara N. Significant correlation between micrometastasis in the lymph nodes and reduced expression of E-cadherin in early gastric cancer. Gastric Cancer. 2001;4:66–74.CrossRefPubMed
52.
Yoshii T, Miyagi Y, Nakamura Y, Kobayashi O, Kameda Y, Ohkawa S. Pilot research for the correlation between the expression pattern of E-cadherin-beta-catenin complex and lymph node metastasis in early gastric cancer. Tumori. 2013;99:234–8.PubMed
53.
Blok P, Craanen ME, Dekker W, Tytgat GN. Loss of E-cadherin expression in early gastric cancer. Histopathology. 1999;34:410–5.CrossRefPubMed
54.
Shun CT, Wu MS, Lin MT, Chang MC, Lin JT, Chuang SM. Immunohistochemical evaluation of cadherin and catenin expression in early gastric carcinomas: correlation with clinicopathologic characteristics and helicobacter pylori infection. Oncology-Basel. 2001;60:339–45.CrossRef
55.
Yi KD, Kyoon JJ, Kyu PY, Yeob RS, Soo KH, Kyun NB, et al. E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis. J Surg Oncol. 2007;96:429–35.CrossRef
56.
Joo YE, Rew JS, Choi SK, Bom HS, Park CS, Kim SJ. Expression of e-cadherin and catenins in early gastric cancer. J Clin Gastroenterol. 2002;35:35–42.CrossRefPubMed
57.
Xiangming C, Hokita S, Nuruki K, Toyoyama H, Tanabe G, Baba M, et al. The expression of cadherin-catenin complex in association with the clinicopathologic features of early gastric cancer. Surg Today. 1998;28:587–94.CrossRefPubMed
58.
Chen C, Yang JM, Hu TT, Xu TJ, Yan G, Hu SL, et al. Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. Arch Med Res. 2013;44:380–9.CrossRefPubMed
59.
Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007;31:1458–68.CrossRefPubMed
Metadata
Title
Predictable factors for lymph node metastasis in early gastric cancer analysis of clinicopathologic factors and biological markers
Authors
Yi-Wei Wang
Mei-Ling Zhu
Rui-Fen Wang
Wen-Ji Xue
Xue-Ru Zhu
Li-Feng Wang
Lei-Zhen Zheng
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4721-3

Other articles of this Issue 7/2016

Tumor Biology 7/2016 Go to the issue

Original Article

Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients

Original Article

Circulating serum levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and larynx carcinoma patients

Original Article

High TXNDC5 expression predicts poor prognosis in renal cell carcinoma

Original Article

GRIM-19 inhibition induced autophagy through activation of ERK and HIF-1α not STAT3 in Hela cells

Original Article

The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells

Original Article

Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits